drugset / Trial / NCT02365285
Racial Differences in Vagal Control of Glucose Homeostasis
Phase 1/2
Completed
23 enrolled
Vanderbilt University Medical Center
Doris Duke Charitable Foundation · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.
Timeline
- Start
- 2015-03
- Primary completion
- 2017-10-05
- Completion
- 2017-10-05
Outcome
Met primary endpoint
paper Compared to placebo, 16 mg of galantamine significantly inhibited the increase in F2-IsoPs in PBMC (0.007 ± 0.008 vs. - 0.002 ± 0.006 ng/sample, P = 0.016) PMID 35659521 ↗
paper Compared to placebo, 16 mg of galantamine significantly inhibited the increase in F2-IsoPs in PBMC PMID 35659521 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 16 mg | Oral |
| Background | Heparin | Other / unclassified | 200 iu | Intravenous |
| Background | Intralipid | Other / unclassified | 0.8 ml | Intravenous |
| Background | Intralipid | Other / unclassified | 20 % | Intravenous |